Our consultant directory offers information on who our consultants are, their specialities and where they are based.
If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.
Our consultant directory offers information on who our consultants are, their specialities and where they are based.
If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.
Dr Brown is a paediatric respiratory consultant and lead for the tertiary respiratory service at the Royal London Hospital. The service provides specialist multi-disciplinary respiratory care to children within East London and beyond with complex respiratory issues.
Dr Brown qualified from Royal Free and University College Medical School, University College London in 2000, where she was also awarded a Bachelor of Science in Immunology and Cell Pathology. She trained in paediatric respiratory medicine in several highly regarded centres including the Royal Brompton Hospital, Great Ormond Street Hospital and the Royal London Hospital, and underwent bronchoscopy training at Cincinnati Children’s Hospital, USA. She was awarded a doctorate by Imperial College London for research undertaken within the Lloyd Lab, Leukocyte Biology Department, and the National Heart & Lung Institute of the Royal Brompton Hospital.
As well as overall lead for the paediatric respiratory service, Dr Brown is lead for bronchiectasis, primary ciliary dyskinesia and the respiratory care of children with immunodeficiency and neurodisability.
Skyline 102 VX20-121-102 and VX20-121-103 (Vertex Pharmaceuticals) Studies evaluating safety of a new modulator VX-121 for patients with cystic fibrosis
MAGNIFY VX20-CFD-004 (Vertex Pharmaceuticals) A study on the quality of life for cystic fibrosis patients treated with Orkambi® or Symkevi® and their caregivers
Skyline 104 VX20-121-104 (Vertex Pharmaceuticals) A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects with CF
4 WHIM X4P-001-103 (X4 Pharmaceuticals) Phase 3 randomised double-blind placebo-controlled multicentre study of Mavorixafor in patients with WHIM syndrome with open label extension
CF STORM NIHR / University of Liverpool A randomised open label trial to assess change in respiratory function for people with CF established on triple combination therapy (KaftrioTM) after rationalisation of nebulised mucoactive therapies.
CF START NIHR/ University of Liverpool CF anti-staphylococcal antibiotic prophylaxis trial
VX20-CFD-005 TRAJECTORY (Vertex Pharmaceuticals) A longitudinal study on the impact of ELX/TEZ/IVA treatment in patients with CF in the real world
We know some websites can be confusing and hard to navigate.
Please complete this short survey about your experience today